SEDG SolarEdge Technologies tops Q4 2025 earnings estimates shares rise nearly 4 percent on 31 percent annual revenue growth Illumina Inc ILMN Launches DRAGEN v45 Software to Expand Genomic Analysis Capabilities Across HighGrowth Segments SCSC ScanSource reports Q1 2026 224 EPS miss and 67 YoY revenue decline amid broad market headwinds Charter Communications Inc CHTR PreQ1 2026 Earnings Preview Mixed Operating Trends and NearTerm Headwinds Ahead of Results Release Marathon Petroleum Corporation MPC Consecutive Insider Disposals Signal Potential NearTerm Bearish Risks How Yiren YRD handles its debt maturity schedule MBC MasterBrand stock posts modest gains even after Q4 2025 EPS misses Wall Street forecasts by a wide margin TDOC Teladoc Health shares gain 66 percent even as Q1 2026 EPS misses Wall Street analyst estimates News Analysis Microsoft Google and xAI will let the government test their AI models before la GoPro Considers Strategic Alternatives Following Acquisition Interest Applied Optoelectronics Lumentum and Coherent Slide as AI Optics ProfitTaking Intensifies HCW Biologics HCWB Q4 2025 Earnings Miss EPS 319 vs 086 Expected Strategy Inc Raises 2 Billion Through Stock Sale Adds 24869 Bitcoin to Corporate Treasury Revvity RVTY Q1 2026 Earnings EPS 106 Beats Estimates Social Commerce Partners Warrant SCPQW Surges 125 as Speculative Interest Returns Quantum Computing Stocks Surge as US Unveils 2 Billion Funding Plan with Equity Stakes Bond Market Signals Concern Over Feds Inflation Response as Warsh Takes the Helm SHOP Q1 2026 Earnings EPS Beats Estimates by 676 Stock Rises QSI Q1 2026 Earnings NarrowerthanExpected Loss Drives Stock Higher Daxor Corporation DXR Q3 2007 Earnings Landmark EPS Beat Lifts Sentiment Despite No Revenue Disclosure Quantum Corporation QMCO Q1 2026 Earnings EPS Surpasses Expectations Amid Ongoing Restructuring RRC Q1 2026 Earnings EPS Surges Past Estimates with 19 Beat Amid Strategic Operations PCGH Pacific stakeholders seek clarity on latest quarterly results as initial earnings disclosures remain limited Kalaris Therapeutics Q1 2026 Earnings NarrowerThanExpected Loss Highlights Cost Discipline Amid PreRevenue Biotech